Amgen

Report: Innovation trends in treatments for rare diseases and widespread conditions

Wednesday, June 17, 2015 08:45 AM

The antibiotics market is at risk of losing another decade to inadequate levels of research and innovation, according to international intellectual property firm Marks & Clerk’s new report From rare to routine—medicines for rare diseases, vaccines and antibiotics. Research highlights the striking difference between research levels into rare diseases, vaccines and antibiotics across the globe.

More... »


Halozyme names Laurie Stelzer CFO

Monday, June 8, 2015 01:16 PM

Halozyme Therapeutics, an oncology biotech company headquartered in San Diego, has announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume chief financial officer  duties on June 15 and will work with Ramsay through a transition period.

More... »


Amgen launches program to further advance basic biology research

Monday, June 1, 2015 10:47 AM

Amgen has created a catalog of qualified tools and reagents available to academic institutions to help further research and advance basic discoveries in biology, as well as deepen relationships with academic institutions. This catalog and its associated materials are called the Amgen Biology-Enabling Resource (AmBER). 

More... »

Amgen releases phase III AMG 416 data for secondary hyperparathyroidism in CKD

Friday, May 29, 2015 01:46 PM

Amgen has released pooled data from two pivotal phase III, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving hemodialysis. Both studies met the primary endpoint, demonstrating that a greater proportion of patients in the AMG 416 groups achieved a greater than 30% reduction in parathyroid hormone (PTH) during the efficacy assessment phase compared with placebo.

More... »

Massachusetts Life Sciences Center awards 11 companies tax incentives for 1,075 new jobs

Thursday, April 30, 2015 11:58 AM

The Massachusetts Life Sciences Center (MLSC), an investment agency that supports life sciences innovation, research, development and commercialization, has awarded $19 million in tax incentives to 11 life sciences companies. The recipients have committed to creating 1,075 new jobs in the Commonwealth in 2015.

More... »

Ruthigen, Pulmatrix ink merger agreement

Monday, March 16, 2015 01:41 PM

Ruthigen, a biopharmaceutical company based in Santa Rosa, Calif., and Pulmatrix, a Lexington, Mass.-based clinical stage biotech, have entered into a definitive merger agreement. Pulmatrix will become a wholly-owned subsidiary of Ruthigen and all of Pulmatrix's debt and equity securities outstanding prior to the consummation of the merger will be exchanged for shares of Ruthigen common stock that will represent approximately 81% of the outstanding common stock of Ruthigen.

More... »

First U.S. biosimilar approval opens floodgates for lower-priced competition to blockbuster biologics

Monday, March 16, 2015 08:00 AM

The FDA’s approval this month of the first U.S biosimilar, Zarxio from Sandoz, has formally opened the floodgates for sponsors seeking approval of lower-cost biologics to compete with expensive brand-name prescription drugs.

More... »

International GPCR Consortium adds Novo Nordisk and Merck

Wednesday, February 11, 2015 12:34 PM

The GPCR Consortium, an international nonprofit collaboration that comprises academic research institutes in the U.S. and China and major pharma companies around the world, has announced Novo Nordisk and Merck as new members. The companies join AmgenSanofi and Ono in the GPCR Consortium. The research funded by the GPCR Consortium currently is conducted at the Bridge Institute at the University of Southern CaliforniaShanghai Institute of Materia Medica and the iHuman Institute at ShanghaiTech University.

More... »

WuXi PharmaTech acquires NextCODE Health

Friday, January 9, 2015 01:58 PM

WuXi PharmaTech, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries with operations in China and the U.S., has acquired NextCODE Health, a genomic analysis and bioinformatics company with operations in the U.S. and Iceland, for $65 million in cash.

More... »

Amgen, LabCentral to support life sciences and biotech startups in Massachusetts

Monday, January 5, 2015 12:38 PM

Amgen has become a LabCentral platinum sponsor. LabCentral is an innovative, shared laboratory space designed as a launchpad for life sciences and biotech startups. As part of the sponsorship agreement, Amgen can nominate up to two promising life sciences and biotech startup companies per year to take up residence in LabCentral’s Kendall Square facilities, based in Cambridge, Mass.

More... »


CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs